# Stoke Therapeutics (STOK) — Analyst Forecast

STOK · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/stok/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 13 | 0 | 0 | 13 |

## Price target

| Low | Average | High | Analysts |
| --- | --- | --- | --- |
| $35.00 | $46.60 | $60.00 | 5 |

Last price $24.61 (as of Oct 15, 2026).

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Aug 21, 2026 | JP Morgan | Maintained | Overweight | $40.00 |
| Aug 4, 2026 | Chardan Capital | Maintained | Buy | $35.00 |
| Aug 4, 2026 | Canaccord Genuity | Maintained | Buy | $58.00 |
| Aug 4, 2026 | Wedbush | Maintained | Outperform | $40.00 |
| Aug 4, 2026 | Guggenheim | Maintained | Buy | $60.00 |
| Jul 13, 2026 | Goldman Sachs | Initiated Coverage | Buy | $44.00 |
| May 11, 2026 | BTIG | Maintained | Buy | $39.00 |
| Mar 20, 2026 | Canaccord Genuity | Maintained | Buy | $60.00 |
| Mar 19, 2026 | BTIG | Maintained | Buy | $39.00 |
| Mar 18, 2026 | Chardan Capital | Maintained | Buy | $35.00 |
| Mar 18, 2026 | Wedbush | Maintained | Outperform | $38.00 |
| Mar 17, 2026 | Needham | Maintained | Buy | $40.00 |
| Mar 17, 2026 | Wedbush | Maintained | Outperform | $38.00 |
| Feb 24, 2026 | Wolfe Research | Initiated Coverage | Outperform | $40.00 |
| Jan 12, 2026 | Wedbush | Maintained | Outperform | $36.00 |
| Jan 5, 2026 | Canaccord Genuity | Maintained | Buy | $36.00 |
| Jan 5, 2026 | Chardan Capital | Maintained | Buy | $35.00 |
| Dec 15, 2025 | HC Wainwright & Co. | Maintained | Buy | $50.00 |
| Nov 5, 2025 | BTIG | Maintained | Buy | $39.00 |
| Nov 5, 2025 | Wedbush | Maintained | Outperform | $32.00 |

## Frequently Asked Questions

### What is the price target for STOK stock?

The average 12-month analyst price target for Stoke Therapeutics (STOK) is $46.60, with a high estimate of $60.00 and a low of $35.00, across 5 analysts.

### Is STOK a buy, sell, or hold?

Analysts covering Stoke Therapeutics currently average a Buy rating: 13 buy, 0 hold and 0 sell, from 13 analysts. Ratings reflect analyst opinion, not investment advice.

### What upside do analysts see for STOK?

The average price target of $46.60 implies 89.35% upside from the last price of $24.61.

### What is the latest analyst rating on STOK?

On Aug 21, 2026, JP Morgan maintained Stoke Therapeutics at Overweight with a price target of $40.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).